Humanetics’ Treatment for Erectile Dysfunction in Radiation-treated Patients, BIO 300, Given Patent

Humanetics’ Treatment for Erectile Dysfunction in Radiation-treated Patients, BIO 300, Given Patent
Humanetics Corporation has received a U.S. patent for its BIO 300 compound, which it developed to prevent erectile dysfunction in men receiving radiation therapy for prostate cancer. Two professors at the University of Maryland School of Medicine, Dr. Zeljko Vujaskovic, MD, and Dr. Isabel L. Jackson, PhD, developed BIO 300. Preclinical studies a few years ago showed that the compound not only can mitigate radiation-induced erectile dysfunction, but can also improve radiotherapy's ability to kill tumors. The research, "Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer," was publ
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *